Risk-adapted daratumumab quintuplet therapy was linked to less than half the progression risk of an external control in high-risk myeloma at five years

Design

Multicentre phase 2 trial with genetically matched external control (Myeloma XI)

Population

107 patients with newly diagnosed high-risk myeloma or plasma cell leukaemia (UK)

Primary outcome

5-year progression-free and overall survival (primary endpoint 18-month PFS reported earlier)

Effect

PFS HR 0.32 (95% CI 0.22–0.45); OS HR 0.43 (0.28–0.65)

OPTIMUM (MUKnine) was a UK phase 2 trial in 107 patients with newly diagnosed high-risk multiple myeloma, defined by two or more high-risk cytogenetic abnormalities, high-risk gene expression profile, or plasma cell leukaemia. Treatment was intensified throughout: daratumumab, cyclophosphamide, bortezomib, lenalidomide and dexamethasone induction, augmented autologous transplant, two-part extended consolidation, and daratumumab-lenalidomide maintenance. The comparator was a genetically matched external control of 120 patients from Myeloma XI.

At a median 71 months, median progression-free survival was not reached against 24.4 months in the control (HR 0.32, 95% CI 0.22 to 0.45), and overall survival was not reached against 57.4 months (HR 0.43, 0.28 to 0.65). The benefit was consistent across subgroups, which were selected post hoc, except patients with three or more high-risk abnormalities.

The comparison is with a historical, not randomised, control, and Myeloma XI patients did not receive daratumumab. Still, the size and durability of the difference support routine molecular risk testing at diagnosis so that high-risk patients can be offered intensified, extended therapy. The trial was funded by Myeloma UK, BMS and Johnson & Johnson.

• Send cytogenetics (FISH) at myeloma diagnosis; treatment intensity now depends on it.
• In high-risk disease, extended consolidation and dual maintenance was associated with much longer survival.
• In a post-hoc subgroup, patients with three or more high-risk abnormalities did not show the same benefit; consider trial referral.
• In India, daratumumab cost limits access; molecular risk testing still guides who should be prioritised.

Why it matters

It shows high-risk myeloma need not mean short survival if treatment is matched to risk.

Don't overread it

The comparator was an external historical control, not randomised; the subgroup findings were selected after the fact.

The statistics, in plain English

A hazard ratio of 0.32 means about two-thirds lower risk of progression at any time. But the control group came from an older trial without daratumumab, so part of the difference may reflect changes in care over time rather than this regimen alone.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.